Impact Analysis of Phytometabolites on Oncogene Regulation and Tumor Suppression in Cancer Prevention
DOI:
https://doi.org/10.56294/saludcyt20251602Keywords:
Phytometabolites, Oncogene regulation, Tumor suppression, Cancer prevention, Bioactive compoundsAbstract
Phytometabolites, which are beneficial substances that come from plants, have gotten a lot of attention lately because they might help avoid and treat cancer. Flavonoids, terpenoids, alkaloids, and polyphenols are some of these substances. They have many biological actions that change how oncogenes work and how tumors are stopped. This study looks at the molecular and cellular ways that phytometabolites affect important oncogenes and tumor suppressors, which could stop tumors from starting, spreading, and metastasizing. When phytometabolites affect oncogene regulation, they either turn off or on certain signaling pathways that manage cell growth, death, and sprouting. A lot of substances can change the production of oncogenes like c-Myc, K-Ras, and EGFR. These genes are very important in the development of many types of cancer. It is possible for these chemicals to stop the abnormal activity of oncogenes, which stops cells from multiplying and surviving. This could be a good way to avoid cancer. On the other hand, phytometabolites also raise the levels of tumor suppressors like p53, PTEN, and BRCA1/2. These proteins are very important for keeping cells healthy and stopping tumors from growing. Phytochemicals turn on these tumor suppressors, which helps cancer cells fix their DNA, stop the cell cycle, and die. Phytometabolites can also change epigenetic changes that are linked to cancer formation, such as DNA methylation, histone modification, and microRNA control. This may help their chemopreventive benefits even more. Also, the fact that natural goods contain a variety of phytometabolites may make them more effective by working together to target more than one biological process involved in cancer.
References
[1] Marconi, G.D.; Fonticoli, L.; Rajan, T.S.; Pierdomenico, S.D.; Trubiani, O.; Pizzicannella, J.; Diomede, F. Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in wound healing, tissue regeneration and organ fibrosis. Cells 2021, 10, 1587.
[2] Xu, Z.; Zhang, Y.; Dai, H.; Han, B. Epithelial-Mesenchymal Transition-mediated tumor therapeutic resistance. Molecules 2022, 27, 4750.
[3] Dahmardeh Ghalehno, A.; Boustan, A.; Abdi, H.; Aganj, Z.; Mosaffa, F.; Jamialahmadi, K. The potential for natural products to overcome cancer drug resistance by modulation of Epithelial-Mesenchymal Transition. Nutr. Cancer 2022, 74, 2686–2712.
[4] Kim, E.K.; Choi, E.J.; Debnath, T. Role of phytochemicals in the inhibition of epithelial-mesenchymal transition in cancer metastasis. Food Funct. 2016, 7, 3677–3685.
[5] Das, B.; Sarkar, N.; Bishayee, A.; Sinha, D. Dietary phytochemicals in the regulation of epithelial to mesenchymal transition and associated enzymes: A promising anticancer therapeutic approach. Semin. Cancer Biol. 2019, 56, 196–218.
[6] Brabletz, S.; Schuhwerk, H.; Brabletz, T.; Stemmler, M.P. Dynamic EMT: A multi-tool for tumor progression. Embo J. 2021, 40, 108647–108669.
[7] Pouliquen, D.L.; Boissard, A.; Henry, C.; Coqueret, O.; Guette, C. Curcuminoids as modulators of EMT in invasive cancers: A review of molecular targets with the contribution of malignant mesothelioma studies. Front. Pharmacol. 2022, 13, 934534–934559.
[8] Ikenouchi, J.; Matsuda, M.; Furuse, M.; Tsukita, S. Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci. 2003, 116, 1956–1967. [Google Scholar]
[9] Nieto, M.A.; Huang, R.Y.-J.; Jackson, R.A.; Thiery, J.P. EMT: 2016. Cell 2016, 166, 21–45.
[10] Mittal, V. Epithelial Mesenchymal Transition in tumor metastasis. Mol. Oncol. 2018, 11, 28–39.
[11] Kang, E.; Seo, J.; Yoon, H.; Cho, S. The post-translational tegulation of Epithelial-Mesenchymal Transition-inducing transcription factors in cancer metastasis. Int. J. Mol. Sci. 2021, 22, 3591.
[12] Yuki, R. Aberrant activation mechanism of TGF-β signaling in Epithelial-mesenchymal Transition. Yakugaku Zasshi 2021, 141, 1229–1234.
[13] Song, M.Y.; Lee, D.Y.; Yun, S.M.; Kim, E.H. GLUT3 promotes Epithelial-Mesenchymal transition via TGF-β/JNK/ATF2 signaling pathway in colorectal cancer cells. Biomedicines 2022, 10, 1837. [
[14] Zhang, J.; Tian, X.-J.; Xing, J. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. J. Clin. Med. 2016, 5, 41.
[15] Khatra, H.; Bose, C.; Sinha, S. Discovery of Hedgehog antagonists for cancer therapy. Curr. Med. Chem. 2017, 24, 2033–2058.
[16] Xie, J.; Zhou, J.; Xia, J.; Zeng, Y.; Huang, G.; Zeng, W.; Fan, T.; Li, L.; Zeng, X.; Tao, Q. Phospholipase C delta 1 inhibits WNT/β-catenin and EGFR-FAK-ERK signaling and is disrupted by promoter CpG methylation in renal cell carcinoma. Clin. Epigenet. 2023, 15, 30–45.
[17] Martinelli, E.; Morgillo, F.; Troiani, T.; Ciardiello, F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat. Rev. 2017, 53, 61–69.
[18] Majidpoor, J.; Mortezaee, K. Steps in metastasis: An updated review. Med. Oncol. 2021, 38, 3–20.
[19] He, S.J.; Xiang, C.Q.; Zhang, Y.; Lu, X.T.; Chen, H.W.; Xiong, L.X. Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition. Onco Targets Ther. 2017, 10, 3435–3451.
[20] Sun, M.; Sun, M.; Zhang, J. Osthole: An overview of its sources, biological activities, and modification development. Med. Chem. Res. 2021, 30, 1767–1794.
[21] Sun, Y.; Chen, Y.; Liu, T.; Wang, Y.; Wang, Y.; Han, L.; Ma, Z.; Feng, J. Evaluating the efficacy of osthole and matrine for control of Sorghum purple spot. J. Plant Dis. Protect. 2021, 128, 1263–1268.
[22] Jiang, G.; Liu, J.; Ren, B.; Tang, Y.; Owusu, L.; Li, M.; Zhang, J.; Liu, L.; Li, W. Anti-tumor effects of osthole on ovarian cancer cells in vitro. J. Ethnopharmacol. 2016, 193, 368–376.
[23] Yang, S.; Dai, W.; Wang, J.; Zhang, X.; Zheng, Y.; Bi, S.; Pang, L.; Ren, T.; Yang, Y.; Sun, Y.; et al. Osthole: An up-to-date review of its anticancer potential and mechanisms of action. Front. Pharmacol. 2022, 13, 945627.
[24] Liu, L.; Mao, J.; Wang, Q.; Zhang, Z.; Wu, G.; Tang, Q.; Zhao, B.; Li, L.; Li, Q. In vitro anticancer activities of osthole against renal cell carcinoma cells. Biomed. Pharmacother. 2017, 94, 1020–1027.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Manish Trivedi, Jyoti Prakash Samal, Kasturi Pohini, Pradeep S, Shikhar Gupta, Sahil Suri, Anand Gudur (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
